View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Phase II/III Study of N-803 (ALT-803) Plus PembrolizumabVersus Standard of Care in Participants With Stage IV or Recurrent Non-SmallCell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy(Lung-MAP Non-Match Sub-Study)
Investigator: Jiang Li, Ph.D., MPH